Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The employee's share-based award requires continued service through each of three annual vesting dates.

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) granted 333 restricted stock units to one newly hired employee as of September 30, 2026.

The award was an employment inducement under the company's amended 2022 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). Restricted stock units are share-based awards. The award will vest over three years, with 33 1/3% of the underlying shares vesting on each consecutive anniversary of the grant date, subject to continued service as an employee or other service provider through each applicable vesting date.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.333 restricted stock units add potential shareholder dilution, subject to vesting over three years and continued service.

Key Figures

Restricted stock units: 333 RSUs Vesting period: 3 years Annual vesting: 33 1/3%

Restricted stock units

333 RSUs

Granted to one newly hired employee

Vesting period

3 years

Vests on three consecutive anniversaries of the grant date

Annual vesting

33 1/3%

Shares underlying the award vest on each anniversary

Key Terms

restricted stock units

1 terms

restricted stock units financial

"granted 333 restricted stock units (RSUs) to one newly-hired employee"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of September 30, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of the RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

About Karyopharm Therapeutics

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematological cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient, and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

CONTACT:
Brendan Strong
Senior Vice President, Investor Relations
617.762.2661
brendan.strong@karyopharm.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-302894983.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many restricted stock units did Karyopharm grant to its new employee?

Karyopharm granted 333 restricted stock units to one newly hired employee as of September 30, 2026. The award was an employment inducement under the amended 2022 Inducement Stock Incentive Plan.

When does Karyopharm's September 2026 inducement award vest?

The award vests over three years, with 33 1/3% of the underlying shares vesting on each of the three consecutive anniversaries of September 30, 2026. Vesting requires continued service as an employee or other service provider through the applicable vesting dates.